dual glp-1/gip agonist Comparison between GLP-1 RA and the GLP-1 Receptor Agonists Explained for

July 2024, Roche announced that its oral GLP-1 receptor agonist GLP-1 Agonists Target Patient Pool Analysis: between 2014 and 2018, only In a study by Watanabe et al

Short half-life, pleiotropy, and behavioral or cardiovascular effects were historically interpreted as disqualifying features

The reduction of visceral fat is regarded as one of the non-glucose-lowering effects of GLP-1RAs, such as liraglutide [54], which may contribute to myocardial protection

Although diabetic patients commonly use metformin, GLP-1R agonists serve as a beneficial therapeutic option for diabetic patients with metformin intolerance

Lancet Diabetes Endocrinol 6(8):605617 [DOI] [PubMed] [Google Scholar] Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018b) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

They named it a triple agonist because it targets GLP-1, GIP, and glucagon receptors